483 related articles for article (PubMed ID: 16525063)
21. Oxidative stress is increased in C. elegans models of Huntington's disease but does not contribute to polyglutamine toxicity phenotypes.
Machiela E; Dues DJ; Senchuk MM; Van Raamsdonk JM
Neurobiol Dis; 2016 Dec; 96():1-11. PubMed ID: 27544481
[TBL] [Abstract][Full Text] [Related]
22. Transducer of regulated CREB-binding proteins (TORCs) transcription and function is impaired in Huntington's disease.
Chaturvedi RK; Hennessey T; Johri A; Tiwari SK; Mishra D; Agarwal S; Kim YS; Beal MF
Hum Mol Genet; 2012 Aug; 21(15):3474-88. PubMed ID: 22589249
[TBL] [Abstract][Full Text] [Related]
23. Expression of Huntington's disease protein results in apoptotic neurons in the brains of cloned transgenic pigs.
Yang D; Wang CE; Zhao B; Li W; Ouyang Z; Liu Z; Yang H; Fan P; O'Neill A; Gu W; Yi H; Li S; Lai L; Li XJ
Hum Mol Genet; 2010 Oct; 19(20):3983-94. PubMed ID: 20660116
[TBL] [Abstract][Full Text] [Related]
24. Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum.
Grondin R; Kaytor MD; Ai Y; Nelson PT; Thakker DR; Heisel J; Weatherspoon MR; Blum JL; Burright EN; Zhang Z; Kaemmerer WF
Brain; 2012 Apr; 135(Pt 4):1197-209. PubMed ID: 22252996
[TBL] [Abstract][Full Text] [Related]
25. Nucleocytoplasmic trafficking and transcription effects of huntingtin in Huntington's disease.
Truant R; Atwal RS; Burtnik A
Prog Neurobiol; 2007 Nov; 83(4):211-27. PubMed ID: 17240517
[TBL] [Abstract][Full Text] [Related]
26. ATF3 plays a protective role against toxicity by N-terminal fragment of mutant huntingtin in stable PC12 cell line.
Liang Y; Jiang H; Ratovitski T; Jie C; Nakamura M; Hirschhorn RR; Wang X; Smith WW; Hai T; Poirier MA; Ross CA
Brain Res; 2009 Aug; 1286():221-9. PubMed ID: 19559011
[TBL] [Abstract][Full Text] [Related]
27. Quantitative relationships between huntingtin levels, polyglutamine length, inclusion body formation, and neuronal death provide novel insight into huntington's disease molecular pathogenesis.
Miller J; Arrasate M; Shaby BA; Mitra S; Masliah E; Finkbeiner S
J Neurosci; 2010 Aug; 30(31):10541-50. PubMed ID: 20685997
[TBL] [Abstract][Full Text] [Related]
28. Inactivation of Drosophila Apaf-1 related killer suppresses formation of polyglutamine aggregates and blocks polyglutamine pathogenesis.
Sang TK; Li C; Liu W; Rodriguez A; Abrams JM; Zipursky SL; Jackson GR
Hum Mol Genet; 2005 Feb; 14(3):357-72. PubMed ID: 15590702
[TBL] [Abstract][Full Text] [Related]
29. Sirt1 mediates neuroprotection from mutant huntingtin by activation of the TORC1 and CREB transcriptional pathway.
Jeong H; Cohen DE; Cui L; Supinski A; Savas JN; Mazzulli JR; Yates JR; Bordone L; Guarente L; Krainc D
Nat Med; 2011 Dec; 18(1):159-65. PubMed ID: 22179316
[TBL] [Abstract][Full Text] [Related]
30. A new Caenorhabditis elegans model of human huntingtin 513 aggregation and toxicity in body wall muscles.
Lee AL; Ung HM; Sands LP; Kikis EA
PLoS One; 2017; 12(3):e0173644. PubMed ID: 28282438
[TBL] [Abstract][Full Text] [Related]
31. Huntington's disease. Exploiting expression.
Bates GP
Nature; 2001 Oct; 413(6857):691, 693-4. PubMed ID: 11607014
[No Abstract] [Full Text] [Related]
32. Mutant huntingtin represses CBP, but not p300, by binding and protein degradation.
Cong SY; Pepers BA; Evert BO; Rubinsztein DC; Roos RA; van Ommen GJ; Dorsman JC
Mol Cell Neurosci; 2005 Sep; 30(1):12-23. PubMed ID: 15994095
[TBL] [Abstract][Full Text] [Related]
33. Genetic and pharmacological suppression of polyglutamine-dependent neuronal dysfunction in Caenorhabditis elegans.
Parker JA; Holbert S; Lambert E; Abderrahmane S; Néri C
J Mol Neurosci; 2004; 23(1-2):61-8. PubMed ID: 15126693
[TBL] [Abstract][Full Text] [Related]
34. CREB-binding protein sequestration by expanded polyglutamine.
McCampbell A; Taylor JP; Taye AA; Robitschek J; Li M; Walcott J; Merry D; Chai Y; Paulson H; Sobue G; Fischbeck KH
Hum Mol Genet; 2000 Sep; 9(14):2197-202. PubMed ID: 10958659
[TBL] [Abstract][Full Text] [Related]
35. The C. elegans histone deacetylase HDA-1 is required for cell migration and axon pathfinding.
Zinovyeva AY; Graham SM; Cloud VJ; Forrester WC
Dev Biol; 2006 Jan; 289(1):229-42. PubMed ID: 16313898
[TBL] [Abstract][Full Text] [Related]
36. Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington's disease mouse model.
Nguyen T; Hamby A; Massa SM
Proc Natl Acad Sci U S A; 2005 Aug; 102(33):11840-5. PubMed ID: 16087879
[TBL] [Abstract][Full Text] [Related]
37. Reduced Levels of Proteasome Products in a Mouse Striatal Cell Model of Huntington's Disease.
Dasgupta S; Fishman MA; Mahallati H; Castro LM; Tashima AK; Ferro ES; Fricker LD
PLoS One; 2015; 10(12):e0145333. PubMed ID: 26691307
[TBL] [Abstract][Full Text] [Related]
38. Huntingtin-protein interactions and the pathogenesis of Huntington's disease.
Li SH; Li XJ
Trends Genet; 2004 Mar; 20(3):146-54. PubMed ID: 15036808
[TBL] [Abstract][Full Text] [Related]
39. Huntingtin aggregation kinetics and their pathological role in a Drosophila Huntington's disease model.
Weiss KR; Kimura Y; Lee WC; Littleton JT
Genetics; 2012 Feb; 190(2):581-600. PubMed ID: 22095086
[TBL] [Abstract][Full Text] [Related]
40. Adenovirus vector-based in vitro neuronal cell model for Huntington's disease with human disease-like differential aggregation and degeneration.
Dong X; Zong S; Witting A; Lindenberg KS; Kochanek S; Huang B
J Gene Med; 2012 Jul; 14(7):468-81. PubMed ID: 22700462
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
